drugset / Trial / NCT00534703
Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure
Phase 2
Terminated
5 enrolled
Imperial College London
British Heart Foundation · collabCelladon Corporation · collabLeducq Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of the study is to determine the safety and feasibility of giving an adeno-associated viral vector expressing the sarcoplasmic reticulum calcium ATPase (SERCA2a), driven by the CMV promoter (AAV1-CMV-SERCA2a), to heart failure patients that have received a left ventricular assist device (LVAD) for an accepted clinical indication.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-09
- Completion
- 2015-09
Outcome
Outcome not reported
Stopped: “Early termination following Trial Steering Committee recommendation”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | AAV1/SERCA2a | Gene therapy (AAV / viral vector) | 1e+13 unknown | Other |